Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

55 results about "Pigmentation disorder" patented technology

A disorder in which the skin is hyperpigmented or hypopigmented.

Topically applied clostridium botulinum toxin compositions and treatment methods

Hyperactive glandular conditions are treated using topically formulated botulinum toxin compositions. In the preferred embodiment of the invention, topical botulinum preparations are applied directly to the skin by a patient as needed to suppress his or her hyperhidrosis, bromhidrosis, chromhidrosis, nevus sudoriferous, acne, seborrhiec dermatitis or other glandular condition. In other embodiments, topical botulinum toxins are applied with the aid of mechanical, electrical, and / or chemical transdermal delivery enhancers.
Owner:COLEMAN WILLIAM P III

Methods and compositions for treating skin conditions

The invention features methods, kits, and compositions for treating aging-related skin conditions (e.g., wrinkles), pigmentation disorders, acne, and scar formation, as well as methods, kits, and compositions for preventing scar formation.
Owner:PURETECH VENTURES

7-Oxo-DHEA compounds for treating keratinous conditions/afflictions

7-Oxo-DHEA derivatives, various of which are themselves novel compounds, are well suited for cosmetically / therapeutically treating adverse conditions / afflictions of a keratinous substrate / material, notably of human skin, hair, eyelashes and nails, to improve the appearance thereof, in particular to prevent or treat signs of aging of the skin and / or a dull complexion and / or skin or hair pigmentation disorders and / or dryness of the skin and / or hyperseborrhoea and / or hyperseborrhoea-related imperfections and / or sensitive skin and / or dandruff and / or natural hair loss and / or baldness.
Owner:LOREAL SA

Melanin modification compositions and methods of use

A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well as a pharmaceutically acceptable carrier or excipient. Carriers and excipients may be formulated for topical administration. Compositions may also be formulated for transdermal administration. The compositions may be used for the prevention and treatment of pigmentation disorders, by way of non-limited example, post-inflammatory hyperpigmentation and others. The compositions may be used for lightening skin.
Owner:ALLERGAN INC

Nanoparticle compositions

InactiveUS20120328702A1Limit deliveryEffective for topical administrationAntibacterial agentsPowder deliveryDiseaseWrinkle skin
The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and / or conditions associated with the epidermal and / or dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, actinic keratosis, facial wrinkles, muscle contracture, and headache. Methods generally involve administering nanoparticle compositions to the skin.
Owner:ANTERIOS INC

Use of DHEA derivatives on keratinous substances

Methods of improving the appearance of keratinous substances using at least one DHEA derivative such as the skin, hair, eyelashes and / or nails, in particular for preventing or treating cutaneous signs of ageing and / or a faded complexion and / or disorders of pigmentation of the skin or hair and / or drying of the skin and / or hyperseborrhoea and / or imperfections relating to hyperseborrhoea and / or sensitive skin and / or dandruff and / or hair loss and / or canities.
Owner:LOREAL SA

Neuroprotective iron chelators and pharmaceutical compositions comprising them

Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, eg. a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, a inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding ageing, and prevention and / or treatment of skin ageing and skin protection against sunlight and / or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety, the neuroprotective function is imparted to the compound e.g. by a neuroprotective peptide, and a combined antiapoptotic and neuroprotective function by a propargyl group.
Owner:TECHNION RES & DEV FOUND LTD +1

Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions

ActiveUS20100189795A1Produce skin irritationReduce skin pigmentationCosmetic preparationsOrganic active ingredientsHypopigmentationSkin Pigmentation Disorder
The present invention provides compositions containing one or more calcium sequestration agents and methods for topical application of such compositions to the skin to treat skin pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation, pigmentation changes due to skin aging, or any other skin conditions related with normal such as skin of color or abnormal pigmentation such as hypo- or hyper-pigmentation in humans.
Owner:ANTEIS SA

Nanoparticle compositions

InactiveUS20150196490A1Effective for topical administrationLimit deliveryAntibacterial agentsPowder deliveryDiseaseCuticle
The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and / or conditions associated with the epidermal and / or dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, actinic keratosis, facial wrinkles, muscle contracture, and headache. Methods generally involve administering nanoparticle compositions to the skin.
Owner:ANTERIOS INC

Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions

InactiveUS20160030321A1Produce skin irritationOrganic active ingredientsCosmetic preparationsHypopigmentationSkin Pigmentation Disorder
The present invention provides compositions containing one or more calcium sequestration agents and methods for topical application of such compositions to the skin to treat skin pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation, pigmentation changes due to skin aging, or any other skin conditions related with normal such as skin of color or abnormal pigmentation such as hypo- or hyper-pigmentation in humans.
Owner:NEOCUTIS

Nanoparticle compositions and components thereof

The present invention describes systems and methods for treating disorders and / or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and / or actinic keratosis, among others. Methods generally involve administering provided compositions to the skin.
Owner:ANTERIOS INC

Methods of classifying periorbital dyschromia and systems therefor

A method and system for classifying different types of periorbital dyschromia is disclosed. The method includes providing at least one of a predetermined imaging characteristic and a biological characteristic for each of three different types of periorbital dyschromia, and then measuring the appropriate characteristic on a person exhibiting periorbital dyschromia. The type of periorbital dyschromia exhibited by a person can then be determined by comparing the measured value to the predetermined value and selecting the corresponding type of periorbital dyschromia.
Owner:THE PROCTER & GAMBLE COMPANY

Compounds, compositions and methods for preventing skin darkening

InactiveUS20110190229A1Inhibiting and preventing unwanted skin darkeningCosmetic preparationsBiocideAntiperspirantsEther
A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other. The compounds, compositions and formulations of the invention may be used for the prevention of the onset or progression of conditions characterized by unwanted skin darkening, including those that may be causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.
Owner:NEW YORK UNIV

Genes from Chromosome 3, 5 and 11 involved in premature canities

The invention provides a cosmetic or therapeutic method for combating canities and / or stimulating natural pigmentation and / or treating a pigmentation disorder comprising administering at least one polynucleotide fragment comprising 18 consecutive nucleotides, the sequence of which corresponds to all or part of a gene on human chromosome 3 selected from KIAA 042, CCK, CACNA1D, ARHGEF3 and AL133097 genes, or the sequence of which corresponds to all or part of a gene on human chromosome 5 selected from the KLHL3, HNRPA0, CDC25C, EGR1, C5orf6, C5orf7, LOC51308, ETF1, HSPA9B, PCDHA1 to PCDHA13, CSF1R, RPL7, PDGFRB, TCOF1, AL133039, CD74, RPS14, NDST1, G3BP, GLRA1, C5orf3, MFAP3, GALNT10 and FLJ 117151 genes, or the sequence of which corresponds to all or part of a gene on human chromosome 11 selected from the GUCY1A2, CUL5, ACAT1, NPAT, ATM, AF035326, AF035327, AF035328, BC029536, FLJ20535, DRD2, ENS303941, IGSF4, LOC51092, BC010946, TAGLN, PCSK7 and ENS300650 genes, and diagnostic methods employing same.
Owner:LOREAL SA

Nanoparticle compositions and components thereof

The present invention describes systems and methods for treating disorders and / or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and / or actinic keratosis, among others. Methods generally involve administering provided compositions to the skin.
Owner:ANTERIOS INC

Pharmaceutical compositions for cell therapy of pigmentation disorders

The present invention relates to a pharmaceutical composition for cell therapy of pigmentation disorders, which comprises as an active ingredient (a) melanocytes and keratinocytes, or (b) melanocytes and fibroblasts. The cell therapy composition of this invention allows for the first time to treat pigmentation disorders through cell therapy regimen. The present composition comprises as active ingredients a mixed cell preparation of melanocytes and keratinocytes or a mixed cell preparation of melanocytes and fibroblasts such that it induces very effectively pigmentation to treat diseases associated with hypopig mentation such as vitiligo.
Owner:MODERN CELL & TISSUE TECH

Compounds, compositions and methods for preventing skin darkening

A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other. The compounds, compositions and formulations of the invention may be used for the prevention of the onset or progression of conditions characterized by unwanted skin darkening, including those that may be causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.
Owner:NEW YORK UNIV

7-Oxo-DHEA compounds for treating keratinous conditions/afflictions

7-Oxo-DHEA derivatives, various of which are themselves novel compounds, are well suited for cosmetically / therapeutically treating adverse conditions / afflictions of a keratinous substrate / material, notably of human skin, hair, eyelashes and nails, to improve the appearance thereof, in particular to prevent or treat signs of aging of the skin and / or a dull complexion and / or skin or hair pigmentation disorders and / or dryness of the skin and / or hyperseborrhoea and / or hyperseborrhoea-related imperfections and / or sensitive skin and / or dandruff and / or natural hair loss and / or baldness.
Owner:LOREAL SA

Compositions for the treatment of pigmentation disorders and methods for their manufacture

The present invention addresses the problem of excessive discoloration in hydroquinone compositions of a neutral pH. Antioxidants in the hydroquinone phase and inorganic or amino acyl cationic salts of acidic ascorbyl esters, preferably sodium metabisulfite and magnesium ascorbyl phosphate respectively, are effective in stabilizing such hydroquinone compositions, which are used in treatment of pigmentation disorders. Protected retinoid may be added to these compositions for additional skin benefit effects.
Owner:TARO PHARMA US INC

Compositions for the treatment of pigmentation disorders and methods for their manufacture

The present invention addresses the problem of excessive discoloration in hydroquinone compositions of a neutral pH. Antioxidants in the hydroquinone phase and inorganic or amino acyl cationic salts of acidic ascorbyl esters, preferably sodium metabisulfite and magnesium ascorbyl phosphate respectively, are effective in stabilizing such hydroquinone compositions, which are used in treatment of pigmentation disorders. Protected retinoid may be added to these compositions for additional skin benefit effects.
Owner:TARO PHARMA US INC

Genetic method of identifying hemochromatosis

The present invention provides a substantially purified carbohydrate ligand that specifically binds to a leczyme. The invention also provides methods to identify a carbohydrate ligand that specifically binds to a leczyme or a leczyme that specifically binds to a carbohydrate ligand. The invention further provides methods to identify a peptide that binds to the carbohydrate ligand binding site of a leczyme. The present invention provides methods to isolate a carbohydrate ligand or a leczyme and to identify a carbohydrate ligand or a leczyme that modifies the function of a cell and to obtain such functionally modified cells. The invention further provides methods to modify a cell to express a carbohydrate ligand by introducing an expression vector encoding a leczyme into the cell. The invention also provides methods to modulate the immune response to an antigen by administering the antigen and a carbohydrate ligand. In addition, the invention further provides methods to treat a disease state involving a leczyme by administering a carbohydrate ligand that binds the leczyme or by administering a leczyme that has a similar binding specificity to the leczyme involved in the disease state. The invention further provides methods to diagnose a genetic basis for hemochromatosis by detecting a mutation in a class I MHC molecule that reduces it's ability to associate with beta2 microglobulin.
Owner:ROTHENBERG BARRY E

Spliceosome mediated RNA trans-splicing for correction of skin disorders

The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention can be genetically engineered to interact with a specific target pre-mRNA expressed in cells of the skin so as to result in correction of genetic defects responsible for a variety of different skin disorders to encode a reporter molecule or protein that may have therapeutic benefit. The compositions of the invention further include recombinant vectors systems capable of expressing the PTMs of the invention and cells expressing said PTMs. The methods of the invention encompass contacting the PTMs of the invention with specific target pre-mRNA expressed within cells of the skin under conditions in which a portion of the PTM is trans-spliced to a portion of the target pre-mRNA to form a chimeric RNA molecule wherein the genetic defect in the specific gene has been corrected. The present invention is based on the successful trans-splicing of the collagen XVII pre-mRNA thereby establishing the usefulness of trans-splicing for correction of skin specific genetic defects. The methods and compositions of the present invention can be used in gene therapy for treatment of specific disorders of the skin, i.e., genodermatoses, such as epidermal fragility disorders, keratinization disorders, hair disorders and pigmentation disorders as well as cancers of the skin.
Owner:VIRXSYS

Orchid vanda coerulea as a cosmetic active agent

An extract of the orchid Vanda coerulea is used as cosmetic active agent for regulating the cell cycle in the skin to combat or delay the appearance of visible signs of skin aging or slow down the effects thereof. The extract is used in a cosmetic composition or in an anti-aging method for delaying the appearance of signs of skin aging or slowing down the effects thereof to maintain the firmness of the skin and tissues or restore a more radiant complexion to the skin or alternatively combat disorders of pigmentation related to skin aging.
Owner:LVMH RECH

Composition containing extract derived from green tea leafstalk for skin whitening

The present invention relates to a composition containing an extract derived from green tea leafstalks for skin whitening, wherein the composition is safe for the skin and simultaneously has excellent skin-whitening efficacy and high stability. Since the present invention uses green tea leafstalks, which are typically not used and discarded, the present invention has excellent value in terms of using waste resources. In addition, by containing the extract derived from green tea leafstalks, the composition of the present invention is safe for the skin, has high formulation stability, shows an excellent skin-whitening effect which reduces symptoms of pigmentation such as melasma and freckles, and reduces skin darkness and therefore leads to even and bright skin color.
Owner:AMOREPACIFIC CORP

Use of green coffee beans for regulating skin pigmentation disorders

The present invention relates generally to the field of food supplements and / or food products for cosmetic purpose. More specifically, the present invention aims to provide an ingredient containing green coffee beans or an extract thereof for preventing and / or treating hyper-pigmentation of skin, skin color imperfections such as age-spots and other skin disorders characterized by abnormal pigments. The present invention also aims at improving skin tone as well as providing a skin lightening or whitening agent.
Owner:SOC DES PROD NESTLE SA +1

Gsk3b and uses thereof in the diagnostic and treatment of hypopigmentation disorders

The present invention relates to the identification of the glycogen synthase kinase-3 beta (GSK3B or GSK-3P) as a therapeutic target of pigmentation disorder and as biomarker of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Proteins of the WNT signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders

The present invention relates to the identification of proteins of the WNT signaling pathway as therapeutic targets of pigmentation disorder and as biomarkers of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products